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A B S T R A C T
Objective: Increased expression of insulin-like growth factor binding protein 2, IGFBP-2, is associated with many
cancers, though its role in cervical cancer is unclear. The aim of this study was to investigate the expression of
IGFBP-2 protein and the transcriptomics profile of genes involved in the IGF signaling pathway during cervical
cancer development.
Design: Immunohistochemical expression of IGFBP-2 protein was semi-quantitatively assessed in tissue micro-
arrays containing 9 normal cervix, 10 low grade cervical intraepithelial neoplasia (LGCIN), 10 high grade cer-
vical intraepithelial neoplasia (HGCIN) and 42 squamous cell carcinoma (SCC) cases. The gene expression
profiles of IGFBP-2, IGF-1, IGF-1R, PTEN, MDM2, AKT1 and TP53 were determined in three cervical tissue
samples each from normal cervix, human papillomavirus (HPV)-infected LGCIN, HGCIN and SCC, using Human
Transcriptome Array 2.0.
Results: IGFBP-2 protein was highly expressed in the cytoplasm of SCC cells compared to normal cervix
(p = .013). The expression was not significantly associated with CIN grade or SCC stage. Transcriptomics
profiling demonstrated upregulation of IGFBP-2 and TP53 in HGCIN and SCC compared to normal cervix. IGF-1,
IGF-1R and PTEN genes were downregulated in all histological groups. IGF-1 gene was significantly down-
regulated in SCC (p = .031), while PTEN gene was significantly downregulated in HGCIN (p = .012), compared
to normal cervix. MDM2 and AKT1 genes were downregulated in LGCIN and HGCIN, while upregulated in SCC.
Conclusion: In cervical carcinogenesis, IGFBP-2 appears to play an oncogenic role, probably through an IGF-
independent mechanism.
1. Introduction
The IGF binding proteins (IGFBPs) comprise a family of six proteins,
IGFBP1–6, which bind the two peptide ligands of insulin-like growth
factors 1 and 2 (IGF-1 and IGF-2) (Firth and Baxter, 2002). The six
IGFBPs have distinct functional properties. IGFBP-2 is produced in the
liver, and is expressed in many normal tissues including male and fe-
male reproductive tracts, gastrointestinal tissues, liver, gallbladder, and
other tissues (Uhlen et al., 2010). IGFBP-2 exerts its cellular effects
through two main mechanisms; the IGFBP-2-IGF-dependent pathway is
related to its interaction with IGF-1 and IGF-2 for ligand-binding, as
well as components of the extracellular matrix and cell surface pro-
teoglycans. Whereas, the IGF-independent actions are exerted when
IGFBP-2 interacts with integrin receptors or when it induces specific
target genes in the nucleus (Hoeflich et al., 2001; Pollak et al., 2004;
Rosenzweig, 2004; Russo et al., 2015; Weroha and Haluska, 2012; Yau
et al., 2015). The role of IGFBP-2 in tumorigenesis is complex and
evidence is contradictory for the reason that it can act either in a tumor
suppressor or oncogenic manner. IGFBP-2 has been generally shown to
inhibit IGF actions, hence inhibit mitogenesis, differentiation, survival,
and other cellular processes (Russo et al., 2015). This is often attributed
to the ability of IGFBP-2 to compete with IGF for IGF receptors (IGFR)
binding. However, there is also evidence of IGFBP-2 exerting oncogenic
properties that promote cell proliferation, invasion and suppress
apoptosis, through interaction with integrins (Hoeflich et al., 2001;
Pickard and McCance, 2015; Weroha and Haluska, 2012; Yau et al.,
2015). IGFBP-2 has also been shown to correlate with metastasis, using
integrin-dependent mechanisms to reduce cell adhesion, and promote
invasion (Schutt et al., 2004).
Elevated IGFBP-2 serum levels have been reported in various can-
cers (Weroha and Haluska, 2012) including lung (Guo et al., 2013),
colon (Liou et al., 2010; Renehan et al., 2000), prostate (Ho and Baxter,
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1997), ovary (Flyvbjerg et al., 1997), and is often associated with ad-
vanced stage and poor prognosis (Elmlinger et al., 2001; Fukushima
and Kataoka, 2007; Guo et al., 2013; Liou et al., 2010; Sayer et al.,
2005). Though serum levels of IGFBP-2 were found to increase with
squamous cell cervical cancer stage (Zhi et al., 2014), its expression in
the tumor microenvironment is unclear. In tissues, IGFBP-2 protein was
over-expressed in invasive prostatic cancer (Ambrosini-Spaltro et al.,
2011), hepatocellular carcinoma (Zhou et al., 2012), high grade
gliomas and glioblastoma multiforme (Elmlinger et al., 2001;
Fukushima and Kataoka, 2007; Jiang et al., 2006). On the contrary, few
studies reported low or absent immunohistochemical expression of
IGFBP-2 in specific histologic type of cancers, such as clear cell and
mucinous ovarian carcinomas (Wang et al., 2006), as well as adeno-
carcinoma and squamous cell carcinoma of the lung (Yazawa et al.,
2009).
Besides regulation of IGF levels in the circulation, and interactions
with extracellular matrix and integrin receptors, IGFBP-2 also exerts
influence on the proteins within the cell cytoplasm and target genes in
the nucleus via the IGF-dependent pathway (Russo et al., 2015). After
ligand binding with IGF receptors, signals will stimulate intracellular
downstream networks, one of which is the phosphatidylinositol 3-ki-
nase - protein kinase B (PI3K-AKT) system which regulates cell growth,
proliferation, survival, migration and cell invasion (Janku et al., 2018;
Tang et al., 2018; Vivanco and Sawyers, 2002). Dysregulation of the
AKT pathway is linked to several types of cancers (Tang et al., 2018;
Vivanco and Sawyers, 2002). Phosphatase and tensin homolog (PTEN)
is an antagonist to the PI3K-AKT system. Mutations or silencing of the
PTEN tumor suppressor gene can lead to PI3K-signaling deregulation
and reduction of the PTEN enzyme, which eventually causes un-
controlled cell growth and cancer formation (Li et al., 1997; Vivanco
and Sawyers, 2002). PTEN expression has an inverse association with
IGFBP-2 expression in breast cancer and glioma (Dean et al., 2014;
Fukushima and Kataoka, 2007; Levitt et al., 2005; Perks et al., 2007).
AKT may influence cell survival indirectly through phosphorylation and
activation of nuclear factor of kappa B (NF- ĸB) that mediates nuclear
translocation and inhibits apoptotic genes (Romashkova and Makarov,
1999; Vivanco and Sawyers, 2002). AKT can also regulate the p53
tumor suppressor gene through phosphorylation of p53-binding protein
(Vivanco and Sawyers, 2002). The cellular oncoprotein murine double
minute 2 (MDM2) and p53 are linked through a negative feedback loop
in which p53 growth suppressive function is limited in unstressed cells
(Moll and Petrenko, 2003; Nag et al., 2013). TP53 tumor suppressor
gene is inactivated in cancers through several mechanisms, including
p53 protein association with viral proteins and high levels of MDM2
(Momand et al., 1998). MDM2 is also regulated through phosphoryla-
tion by AKT, which allows efficient translocation of MDM2 into the
nucleus where it can bind to p53, resulting in enhanced p53 degrada-
tion (Moll and Petrenko, 2003; Vivanco and Sawyers, 2002). p53 po-
sitively regulates the PTEN promoter, thus inhibiting the PI3K-AKT
activity. In summary, IGFBP-2 can cause cellular effects in an IGF-de-
pendent or IGF-independent manner which triggers downstream cel-
lular mechanisms that are potentially oncogenic.
The transformation of normal cervical epithelial cells into a dis-
tinctive pre-cancerous stage or cervical intraepithelial neoplasia (CIN),
and further into squamous cell carcinoma (SCC) offers a unique ad-
vantage to study the role of IGFBP-2 in cervical carcinogenesis. Our aim
was to investigate the expression of IGFBP-2 protein in the various
stages of cervical cancer development, and to determine the gene ex-
pression profiles involved in the IGF signaling pathway.
2. Material and methods
2.1. Evaluation of immunohistochemical expression of IGFBP-2 protein in
tissue microarrays
Two tissue microarrays (TMA) (BB10011 and CR1003, Biomax USA)
containing 10 cases of normal cervix, 10 low grade cervical in-
traepithelial neoplasia (LGCIN), 10 high grade cervical intraepithelial
neoplasia (HGCIN) and 43 squamous cell carcinoma (SCC) cases, with
two identical tissue cores per case, were immunohistochemically
stained for IGFBP-2 protein. The TMAs were accompanied with the
pathology diagnosis, CIN grade (Bethesda Classification System) and
FIGO staging for SCC cases.
Briefly, after deparaffinization and rehydration, antigen retrieval
was performed by soaking the slides in citrate buffer (10 mM, pH 6.0)
and heated in a microwave oven on low setting for 20 min. After
treatment with peroxidase-blocking solution (Dako, USA), sections
were blocked with 5% bovine serum albumin (Sigma-Aldrich, USA) and
5% goat serum (Biowest, France) in tris-buffered saline Tween-20 (TBS-
T) solution at room temperature for 1 h. Primary rabbit monoclonal
anti-IGFBP2 antibody [EPR3380(2), Abcam] 1:100 dilution was applied
and incubated overnight at 4 °C. Then, biotinylated secondary antibody
goat anti-rabbit IgG H&L (Biotin), (Code No. AB6720, Abcam) was
added for 1 h, followed by incubation with avidin-biotin complex
(R.T.U Vectastain ABC reagent, Vector Laboratories, USA) for 1 h.
Slides were rinsed thrice with TBS-T between the incubation steps. DAB
solution (3,3′-diaminobenzidine in chromogen solution, Dako, USA)
was applied for 10 min, then rinsed and counterstained with Mayer's
haematoxylin (Dako, USA). The slides were dried, mounted and viewed
under a light microscope before scanned using Hamamatsu,
NanoZoomer S60 Digital Slide Scanner. Brown staining signified posi-
tive protein expression. The histoscore was calculated by multiplying
the percentage of positivity score and staining intensity score, as shown
in Table 1. As each case was represented by two cores, an average
histoscore was taken. Endometrial carcinoma was used as positive
control, while for negative control, primary antibody was not added.
2.2. Tissue samples, RNA extraction, Human Transcriptome Array 2.0
Formalin-fixed paraffin-embedded tissues of histologically con-
firmed normal cervix, low grade cervical intraepithelial neoplasia or
CIN 1 (LGCIN), high grade cervical intraepithelial neoplasia comprising
CIN 2 and CIN 3 (HGCIN) and squamous cell carcinoma (SCC) were
retrieved from pathology archives. This part of the study was approved
by the Human Research Ethics Committee of Universiti Sains Malaysia.
Only HPV 16 and/or 18 positive CIN and SCC samples identified by
immunohistochemistry using p16INK4a and HPV16 E6 + HPV18 E6
antibodies, and real time-PCR were included. Altogether there were 12
samples, comprising three samples each of normal cervix as control
(HPV negative), HPV-positive LGCIN, HGCIN and SCC. Laser capture
microdissection was used to dissect the area of interest. Total RNA was
extracted from the cervical epithelium using RNeasy FFPE extraction kit
(Qiagen, Germany). The RNA purity was measured using Nanodrop and
quantified using a bioanalyzer (Agilent, USA).
GeneChip Human Transcriptome Array 2.0 (HTA 2.0) Affymetrix,
USA was used to profile the gene signatures in the different histological
groups. Sensation plus FFPE WT kit (Affymetrix, USA) was used
Table 1
Histoscore method for assessing immunohistochemical expression of IGFBP-2
protein.
Percentage of positivity Score Staining intensity Score
< 1% positive cells 0
1% - 25% positive cells 1 No staining 0
26% - 50% positive cells 2 Weak staining 1
51% - 75% positive cells 3 Moderate staining 2
≥ 75% positive cells 4 Strong staining 3
Final histoscore = percent positivity score X staining intensity score
Score: 0 = Negative
1–3/12 = Low expression
≥ 4/12 = High expression
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according to the manufacturer's protocol. Upon hybridization, the chip
was scanned using Affymetrix GeneChip Scanner 3000. The data was
analyzed by Affymetrix GeneChip Operating Software (GCOS) which
contains qualitative and quantitative analysis for every probe set.
Affymetrix® Transcriptome Analysis Console (TAC) software was used
to determine the IGFBP-2, IGF-1, IGF-1R, PTEN, MDM2 and AKT1
transcriptomic profiles in each histological group compared to normal
cervix.
2.3. Statistical analysis
The association between IGFBP-2 protein expression and histolo-
gical groups as well as clinicopathological parameters were analyzed by
the chi-square test with statistical significance set at p value< .05,
using IBM SPSS V24.0 software package for Windows. Transcriptomic
analysis in HTA 2.0 was performed by comparing gene expression in
each histological group to normal cervix, using one-way ANOVA test
provided by the array software, with significance set at p value < .05.
3. Results
IGFBP-2 immunohistochemical expression was scored on 71 cases
comprising 9 normal cervix, 10 LGCIN, 10 HGCIN and 42 SCC cases.
One case of normal cervix was devoid of squamous epithelium and one
SCC tissue was detached, hence excluded from the analysis. IGFBP-2
protein was localised in the cytoplasm and membrane of cervical
squamous epithelial cells. In the normal cervix, squamous epithelial
cells showed weak staining in suprabasal cells only. In CIN, basal cells
and superficial epithelial cells showed positive staining, while majority
of neoplastic cells in SCC were positive. Stromal inflammatory cells
were positively stained. IGFBP-2 protein was ubiquitously expressed in
68 of 71 cases (95.8%). The histoscore was significantly higher in SCC
compared to normal cervix (p = .002). The histoscores are tabulated in
Table 2 and IGFBP-2 immunohistochemical staining patterns are shown
in Fig. 1. There was no significant association between IGFBP-2 ex-
pression with CIN grade (p = .638) or SCC FIGO Staging System
(p = .441).
Transcriptomic profiles of IGFBP-2, IGF-1, IGF-1R, PTEN, MDM2
and AKT1 genes were compared between each histological group and
normal cervix. The differences in fold change are shown in Fig. 2. The
results demonstrated IGFBP-2 gene downregulation in LGCIN, while
upregulated in HGCIN and SCC groups, compared to normal cervix.
IGF-1, IGF-1R and PTEN genes were increasingly downregulated in the
progression from LGCIN to SCC. Both MDM2 and AKT1 gene expres-
sions were downregulated in LGCIN and HGCIN while upregulated in
SCC. TP53 gene showed upregulation in HGCIN and SCC.
Statistical analysis demonstrated a significant downregulation of
IGF-1 gene expression in SCC compared to normal cervix (p = .031),
while PTEN gene was significantly downregulated in HGCIN compared
to normal cervix (p = .012), depicted in Fig. 2.
4. Discussion
Cervical carcinogenesis is the neoplastic transformation from
normal epithelial cells to cervical intraepithelial neoplasia (CIN), and
further into invasive cancer. Histologically, LGCIN or CIN 1, consists of
dysplastic cells in the lower one-third of the cervical epithelium, while
in HGCIN, comprising CIN 2 and CIN 3, at least two-thirds of the
thickness of the epithelium is affected (Holowaty et al., 1999). The
dysplastic cells hyper-proliferate within the cervical epithelium before
turning cancerous and invading into the deeper subepithelial tissues
with the potential to metastasize. Majority of cervical cancers are as-
sociated with human papillomavirus (HPV) infection especially HPV 18
and 16 (Lorincz et al., 2002; Smith et al., 2007). The viral oncoproteins
E6 and E7, dysregulate the host cell cycle by interacting with tumor
suppressor protein, p53, and retinoblastoma pRb, respectively
(Longworth and Laimins, 2004). These interactions cause cells to pro-
liferate, grow, differentiate, and avert apoptosis.
The IGF system which regulates cell growth, differentiation, and
apoptosis, is partly controlled by IGFBP-2. Both have been demon-
strated to play a role in cancer. It is still unclear whether IGFBP-2 acts in
a tumor suppressor or oncogenic manner in cervical carcinogenesis.
This study aimed to investigate the immunohistochemical expression of
IGFBP-2 protein in cervical tissues through the process of carcinogen-
esis. To further understand the role of IGFBP-2 and IGF-related cellular
mechanisms, transcriptomics profiling of the relevant genes were per-
formed on tissues from normal cervix, HPV-associated LGCIN, HGCIN,
and SCC.
In tumors, IGFBP-2 expression has been demonstrated to be either
up or downregulated depending on the cancer type. In our study, im-
munohistochemical staining of 71 cases in tissue microarrays showed
that IGFBP-2 protein is ubiquitous and present across a wide range of
cervical cells, from normal to dysplastic (CIN) and neoplastic (SCC)
cells. IGFBP-2 expression was significantly higher (histoscore ≥4/12)
in SCC compared to normal cervix (p = .002), but not significantly
different from CIN. Notwithstanding the limited numbers of normal,
LGCIN and HGCIN cases, the results support the role of IGFBP-2 as a
promoter in the neoplastic transformation of cervical cells. Our results
contradict another study in which IGFBP-2 tissue expression was re-
duced in HPV16-associated CIN 3 and invasive cancer, compared to CIN
1 (Pickard et al., 2015). The HPV status of cases in our tissue micro-
arrays was unknown.
The localization of IGFBP-2 in the cytoplasm and membranes of
squamous epithelial cells in our study alludes to its possible interaction
with the extracellular matrix components, cell surface proteoglycans
and integrin receptors on the cell membrane. IGFBP-2 may be imported
into the cell cytoplasm where it can interact with other transcription
factors, cytoplasm-nuclear transporters and cell cycle inhibitors such as
p21 and Pim-1 associated protein-1 (PAP-1)-associated protein-1
(PAPA-1) (Yau et al., 2015). The nuclear import of IGFBP-2 promotes
transcriptional activation of specific genes (Azar et al., 2014; Russo
et al., 2015; Yau et al., 2015). Though nuclear localization has been
Table 2





Comparison between all histological groups
p value








Normal 0 (0.0) 7 (77.8) 2 (22.2) 9 (100)
LGCIN 1 (10.0) 3 (30.0) 6 (60.0) 10 (100) 0.102
HGCIN 1 (10.0) 5 (50.0) 4 (40.0) 10 (100) 0.013 0.377
SCC 1 (2.4) 8 (19.1) 33 (78.6) 42 (100) 0.002
Total 3 (4.2) 23 (32.4) 45 (63.4) 71 (100)
Chi-square test, statistical significance set at p value< .05.
Abbreviations: LGCIN, low grade cervical intraepithelial neoplasia; HGCIN, high grade cervical intraepithelial neoplasia; SCC, squamous cell carcinoma.
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reported in some cancer cell lines (Azar et al., 2014), our study did not
exhibit nuclear staining of cervical cells, suggesting this mechanism was
not significantly involved in cervical carcinogenesis. This was in con-
cordance with another report demonstrating immunohistochemical
cytoplasmic staining of cervical epithelium (Pickard et al., 2015). It was
interesting to note that the stromal inflammatory cells were positively
stained in our study, reflecting the presence of IGFBP-2 in many types of
tissue including the immune system.
IGFBP-2 was upregulated in SCC at gene and protein levels in our
study. Under these circumstances, IGFBP-2 would competitively bind to
the ligand IGF-1 to limit the interaction with IGF-1R, hence reducing
IGF-mitogenic activity. Concomitantly, IGF-1 and IGF-1R genes were
downregulated, with IGF-1 being significantly downregulated in cer-
vical cancer compared to normal cervix (p = .031). This suggests that
the IGFBP-2-IGF dependent pathway did not play a crucial role in
cervical cancer development. This adds to the contradictory results
obtained by other researchers, clearly summarized and discussed by
Durzyńska (Durzyńska, 2014). While most studies support increased
IGFs levels in serum or tissue in cervical cancer progression (Lee et al.,
2010; Wu et al., 2003), others observed reductions of IGFs or IGFRs
(Schaffer et al., 2007; Serrano et al., 2007; Serrano et al., 2006). An in
vivo study on CIN lesions showed that IGFBP-2 expression was reduced
as the disease progressed from CIN 1 to CIN 3, leading to activation of
the IGF/IGFR pathways (Pickard et al., 2015). This contrasted with our
findings of increased IGFBP-2 gene expression in HGCIN and SCC.
In our study, the transcriptome profile of IGFBP-2 was comparable
to TP53 expression. Both genes were upregulated in HGCIN and SCC
groups. In HPV-associated cervical cancer, it has been established that
E6 binds to p53, causing inhibition of apoptosis (Longworth and
Laimins, 2004), a key factor allowing DNA-damaged cells to proliferate
and transform into cancerous cells. IGFBP-2 has been proposed to be
regulated by p53, which in turn inhibits IGF-1 signaling (Grimberg
et al., 2006), as observed in our study.
PTEN is a tumor suppressor gene which is frequently mutated in a
variety of human cancers and is associated with tumor progression (Li
et al., 1997; Mehrian-Shai et al., 2007). At the cellular level, the ex-
pression of IGFBP-2 is influenced by the functional status of PTEN
(Dean et al., 2014; Levitt et al., 2005; Mehrian-Shai et al., 2007; Perks
et al., 2007). Loss of function of PTEN in cancers is often associated
with high levels of IGFBP-2 expression. Studies conducted on breast and
glioma cell lines support the inverse relationship between IGFBP-2 and
PTEN (Fukushima and Kataoka, 2007; Levitt et al., 2005; Perks et al.,
2007). Loss of PTEN in triple negative breast cancer was associated with
increased immunohistochemical expression of IGFBP-2 (Dean et al.,
2014). Our findings concur, exhibiting an inverse relationship between
PTEN and IGFBP-2 gene expressions in HGCIN and SCC groups. PTEN
gene was significantly downregulated in HGCIN compared to normal
cervix (p = .012), which may offer a growth advantage in the pro-
gression from a precancerous state to cancer. IGFBP-2 appears to exert
an oncogenic potential, which is independent of IGF. This signaling may
be mediated via integrin receptors, leading to inhibition of PTEN, which
in turn activates the AKT pathway, contributing to cell survival and
proliferation (Kumar, 1998; Uzoh et al., 2011).
Binding of IGF-1R to ligand stimulates intracellular activities that
regulate cell survival and proliferation. The PI3-AKT pathway plays a
critical role in the activation of anti-apoptotic factor, MDM2 and pro-
inflammatory factor, NF- ĸB (Mayo and Donner, 2001; Vivanco and
Sawyers, 2002). Phosphorylation of MDM2 by AKT promotes its nuclear
translocation and binding to p53 tumor suppressor gene leading to
degradation of p53 (Mayo and Donner, 2001; Moll and Petrenko, 2003;
Vivanco and Sawyers, 2002). Similarly, AKT causes phosphorylation
followed by translocation of NF- ĸB from the cytoplasm into the
Fig. 1. Digital scanned images of IGFBP-2 immunohistochemical staining showing brown staining in cytoplasm of cervical epithelial cells. (A) Histoscore 4/12, in
LGCIN (x 20 objective); (B) Histoscore 12/12 in SCC (x 10 objective); (C) Histoscore 0/12 in HGCIN (x 10 objective). (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
Abbreviations: LGCIN, low grade cervical intraepithelial neoplasia; HGCIN, high grade cervical intraepithelial neoplasia; SCC, squamous cell carcinoma
Fig. 2. Transcriptomic profiles of IGFBP-2, IGF-1,
IGF-1R, PTEN, MDM2 and AKT1 in LGCIN, HGCIN
and SCC obtained from Human Transcriptome Array.
Bars represent the fold change in each histological
group compared to normal cervix. One-way ANOVA
was done using the array software. * represents p
value< .05.
Abbreviations: LGCIN, low grade cervical in-
traepithelial neoplasia; HGCIN high grade cervical
intraepithelial neoplasia; SCC, squamous cell carci-
noma; AKT, protein kinase B; IGFBP-2, insulin-like
growth factor binding protein; IGF-1, insulin-like
growth factor 1; IGF-1R, insulin-like growth factor 1
receptor; MDM2, murine double minute 2; NF- ĸB,
nuclear factor of kappa B; PI3-K, phosphatidylino-
sitol 3-kinase; PTEN, phosphatase and tensin
homolog
G. Kaur, et al. Experimental and Molecular Pathology 113 (2020) 104362
4
nucleus, allowing activation of target genes (Vivanco and Sawyers,
2002). Hyperactivation of the PI3K-AKT pathway in tumors has been
shown to promote cancer cell proliferation, survival, and invasion
(Tang et al., 2018). The results of our study showed downregulation of
AKT1 and MDM2 in LGCIN and HGCIN, while upregulated in SCC,
suggesting cancer cells acquire cell survival and anti-apoptotic prop-
erties.
In postulating the IGF system mechanisms involved in cervical
cancer development, it is important to appreciate the different stages of
tumor progression (Fig. 3). In the initial stage, the integration of HPV
oncoproteins into the host cells causes deregulation of the cell cycle,
leading to cell proliferation. During this period, the virus attempts to
evade the host immune system (Gius et al., 2007). In our study, IGFBP-2
was downregulated in LGCIN, while the various genes involved in the
IGF system showed one to two-fold change difference compared to
normal cervix. The IGF signaling pathway did not appear to play a
crucial role during this phase. Subsequently, hyper-proliferation and
anti-apoptotic mechanisms become crucial in transforming HGCIN into
SCC (Niu et al., 2017). Our results exhibited an upregulation of IGFBP-2
associated with downregulation of IGF-1, IGF-1R and PTEN genes
during these stages, suggesting the role of IGF-independent mechanisms
in promoting cell proliferation. In SCC, IGFBP-2 inhibits PTEN, thus
activating the AKT and MDM2 signaling pathways, and promoting cell
proliferation and cell survival. The membrane localization of IGFBP-2
protein in CIN and cancer cells implies that it may bind to cell surface
proteoglycans or integrin receptors to indirectly promote oncogenesis
via IGF-independent actions. Additionally, cytoplasmic IGFBP-2 may
trigger other proteins encouraging carcinomatous change. Further re-
search is warranted to identify the specific cellular mechanisms in-
volved.
5. Conclusion
We postulate that IGFBP-2 plays an oncogenic role in cervical
cancer through the IGF-independent mechanism.
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